Cosmo Pharmaceuticals
C43.F
#4884
Rank
$1.23 B
Marketcap
$75.60
Share price
0.00%
Change (1 day)
25.25%
Change (1 year)

P/E ratio for Cosmo Pharmaceuticals (C43.F)

P/E ratio at the end of 2022: 55.2

According to Cosmo Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.4885. At the end of 2022 the company had a P/E ratio of 55.2.

P/E ratio history for Cosmo Pharmaceuticals from 2009 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202255.229.74%
202142.5-137.1%
2020-115208.44%
2019-37.2-34.07%
2018-56.419.54%
2017-47.2-143.22%
20161091312.07%
20157.73238.52%
20142.286.71%
20132.14-71.9%
20127.61-63.45%
201120.8-51.81%
201043.257.48%
200927.4

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.